Scalp cooling is a simple treatment that can prevent hair loss
caused by certain chemotherapy drugs
Paxman has been pioneering scalp cooling technology worldwide for over 25 years. When Sue Paxman lost her hair while receiving chemotherapy for breast cancer, her family shared her distress. Sue's husband, Glenn Paxman founded Paxman on the back of this experience and to this day they remain a close family business. Knowing first-hand the effects that both cancer and its treatment can have on patients, friends and families, their business is much more than just a job. They aim to make a difference to people’s lives by raising awareness about scalp cooling and establishing the cold cap as common practice for all patients undergoing treatment.
Clinically proven cold cap system has helped over 100,000 cancer patients in more than 25 countries worldwide to retain their hair during chemotherapy.
Scalp cooling (the cold cap) can be used with all solid tumor cancers that are treated with chemotherapy drugs such as taxanes (i.e. docetaxel), alkylating agents (i.e. cyclophosphamide) and anthracyclines/DNA intercalating agents (i.e. doxorubicin).
The cold cap reduces the temperature of the scalp reducing the blood flow to the hair follicles which will minimize hair loss. The Paxman system is able to keep the scalp cooled to the proper temperature without having to change caps throughout the infusion.
Summit Medical Group participated in the clinical trial which helped gain FDA clearance.
Those who underwent scalp cooling were significantly more likely to have less than 50% hair loss compared with no scalp cooling (50.5% vs 0%)